Crystal structure of a Chimeric Antigen Receptor (CAR) scFv domain rearrangement forming a VL-VL dimer
暂无分享,去创建一个
David R. Bell | W. Hendrickson | J. Kochenderfer | J. Cheung | Philippe Youkharibache | Shagun Wazir
[1] Devlina Chakravarty,et al. AlphaFold2 fails to predict protein fold switching , 2022, bioRxiv.
[2] Frank D. Teets,et al. AlphaFold accurately predicts distinct conformations based on oligomeric state of a de novo designed protein , 2022, bioRxiv.
[3] Brandon Yushan Feng,et al. Benchmarking AlphaFold for protein complex modeling reveals accuracy determinants , 2021, bioRxiv.
[4] David R. Bell,et al. Evolution of Thyroglobulin Loop Kinetics in EpCAM , 2021, Life.
[5] S. Ovchinnikov,et al. ColabFold: making protein folding accessible to all , 2022, Nature Methods.
[6] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[7] D. Dimitrov,et al. Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22 , 2021, The Journal of biological chemistry.
[8] Yong Gu Lee,et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells , 2021, Nature Network Boston.
[9] J. Castro,et al. Chimeric Antigen Receptor T Cell Therapy in Oncology - Pipeline at a glance: Analysis of the ClinicalTrials.gov database. , 2021, Critical reviews in oncology/hematology.
[10] S. Rosenberg,et al. Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma , 2019, Nature Medicine.
[11] Nathan H. Roy,et al. Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy , 2019, Blood.
[12] C. June,et al. Engineered T Cell Therapies from a Drug Development Viewpoint , 2019, Engineering.
[13] Jiyao Wang,et al. iCn3D, a web-based 3D viewer for sharing 1D/2D/3D representations of biomolecular structures , 2019, Bioinform..
[14] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[15] X. Chen,et al. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. , 2017, Drugs of today.
[16] Stuart A. Sievers,et al. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] N. Taylor,et al. CAR T‐cell therapy of solid tumors , 2017, Immunology and cell biology.
[18] K. Lindorff-Larsen,et al. Understanding single‐pass transmembrane receptor signaling from a structural viewpoint—what are we missing? , 2016, The FEBS journal.
[19] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[20] C. June,et al. Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies , 2015, Immunological reviews.
[21] I. Wilson,et al. Malachite green mediates homodimerization of antibody VL domains to form a fluorescent ternary complex with singular symmetric interfaces. , 2013, Journal of molecular biology.
[22] Serge Muyldermans,et al. Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.
[23] S. Rosenberg,et al. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.
[24] I. Pastan,et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.
[25] Michael J. Bevan,et al. CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.
[26] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[27] B. Volkman,et al. A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. , 2010, Structure.
[28] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[29] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[30] Mitchell Ho,et al. Identification and characterization of fully human anti-CD22 monoclonal antibodies , 2009, mAbs.
[31] S. Rosenberg,et al. Adoptive cell therapy for the treatment of patients with metastatic melanoma. , 2009, Current opinion in immunology.
[32] F. Wurm,et al. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. , 2008, Biotechnology and bioengineering.
[33] Brian G Fox,et al. A combined approach to improving large-scale production of tobacco etch virus protease. , 2007, Protein expression and purification.
[34] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[35] M. Little,et al. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. , 2004, Protein engineering, design & selection : PEDS.
[36] A. Wu,et al. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. , 2003, Journal of molecular biology.
[37] M. Schiffer,et al. A domain flip as a result of a single amino-acid substitution. , 1998, Structure.
[38] C. Jarzynski. Equilibrium free-energy differences from nonequilibrium measurements: A master-equation approach , 1997, cond-mat/9707325.
[39] A. Brünger,et al. Comparison of crystal structures of two homologous proteins: structural origin of altered domain interactions in immunoglobulin light-chain dimers. , 1994, Biochemistry.
[40] R. Poljak. Production and structure of diabodies. , 1994, Structure.
[41] K. D. Hardman,et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.
[42] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[43] C. Chothia,et al. Domain association in immunoglobulin molecules. The packing of variable domains. , 1985, Journal of molecular biology.
[44] J. Novotný,et al. Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[45] R. Huber,et al. The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution. , 1975, Biochemistry.
[46] Serge X. Cohen,et al. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 , 2008, Nature Protocols.
[47] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.